en · de · es · fr · pt
semax-notes.peptides4800.com › Info › Semax Background And Mechanism — What the Evidence Shows

Semax Background And Mechanism — What the Evidence Shows

By Editorial Desk · published 2025-09-27 · last reviewed 2025-10-22 · Info

The short version of RP-HPLC fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2025-10-22. Anything still debated is marked as such rather than presented as settled.

Semax Background And Mechanism

The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.

Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.

Storage Handling and Analytical Verification

Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.

Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.

Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.

Semax at a glance

PropertyValueNotes
Molecular formulaC37H51N9O10SCalculated for the free peptide
Molar mass813.9 g/molAnhydrous free base
Peptide classSynthetic heptapeptideACTH(4-10) analogue
Parent fragmentACTH(4-10)Adrenocorticotropic hormone segment
Developmental originInstitute of Molecular Genetics, MoscowWork began in the 1980s

Semax Background and Chemistry

Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.

The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.

Related pages on this site

Handling, Storage, and Research Status

Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.

Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.

研发背景与监管地位

各国监管态度分化明显。俄罗斯按处方药管理,部分东欧国家留有使用记录;欧盟与美国未批准其作为药物上市,市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录,跨境携带则受目的地药品法规约束。

Semax 是人工设计的七肽,序列为 Met-Glu-His-Phe-Pro-Gly-Pro,骨架取自促肾上腺皮质激素片段 ACTH(4-10)。它于二十世纪八十年代在苏联的分子遗传学研究机构内合成。设计目标是保留该片段与注意力和记忆相关的活性,同时剔除促皮质激素释放等内分泌作用。此后俄罗斯将其登记为药品并进入临床使用。

Supporting material

Before the 20th century, babies born with congenital lactase deficiency often did not survive, but death rates decreased with soybean-derived infant formulas and manufactured lactose-free dairy products.

About half of all cases are inherited from a parent who has the condition. The condition is inherited in an autosomal dominant pattern, which means only one copy of the altered gene is necessary to cause the disorder. The other half of cases occur in patients whose families have no history of the disorder. These sporadic cases are caused by new mutations in one copy of the COL3A1 gene. The protein determined by the COL3A1 gene is used to assemble larger type III collagen molecules, found mostly in skin, blood vessels, and internal organs. When the structure or production of type III collagen is altered by a mutation in the COL3A1 gene, collagen fibrils cannot be assembled properly in these tissues, which causes the symptoms of Ehlers-Danlos syndrome.

==== Antidepressants ==== Antidepressants are one of the common drugs for fibromyalgia. Antidepressants can improve the quality of life for fibromyalgia patients in the medium term. Duloxetine and milnacipran have good evidence of substantial pain relief, with no increased risk for serious adverse effects. A 2023 meta-analysis found that duloxetine improved fibromyalgia symptoms, regardless of the dosage. SSRIs may be also be used to treat depression in people diagnosed with fibromyalgia. While amitriptyline has been used as a first-line treatment, the quality of evidence to support this use is poor. Very weak evidence indicates that a very small number of people may benefit from treatment with the tetracyclic antidepressant mirtazapine, however, for most, the potential benefits are not great and the risk of adverse effects and potential harm outweighs any potential for benefit. Tentative evidence suggests that monoamine oxidase inhibitors (MAOIs) such as pirlindole and moclobemide are moderately effective for reducing pain. Very low-quality evidence suggests pirlindole as more effective at treating pain than moclobemide. Side effects of MAOIs may include nausea and vomiting. For sleep quality, there is no good evidence showing that amitriptyline, milnacipran or duloxetine give improvement.

Some literature even describes unique cases where muscle pain, cramping, and elevated creatine kinase levels are the only presenting symptoms instead of the classic presentation of muscle weakness.Becker muscular dystrophy occurs in approximately 1.5 to 6 in 100,000 male births, making it much less common than Duchenne muscular dystrophy. Symptoms usually appear in men at about ages 8–25, but may sometimes begin later. Genetic counseling may be advisable when potential carriers or patients want to have children. Sons of a man with Becker muscular dystrophy do not develop the disorder, but daughters will be carriers (and some carriers can experience some symptoms of muscular dystrophy), so the daughters' sons may develop the disorder.

Other low-carbohydrate diets in the 1960s included the Air Force diet, "Martinis & Whipped Cream" in 1966, and the Drinking Man's Diet. In 1972, Robert Atkins published Dr. Atkins' Diet Revolution, which advocated the low-carbohydrate diet he had successfully used in treating people in the 1960s. The book was a publishing success, but was widely criticized by the mainstream medical community as being dangerous and misleading, thereby limiting its appeal at the time. The concept of the glycemic index was developed in 1981 by David Jenkins to account for variances in speed of digestion of different types of carbohydrates. This concept classifies foods according to the rapidity of their effect on blood sugar levels – with fast-digesting simple carbohydrates causing a sharper increase and slower-digesting complex carbohydrates, such as whole grains, a slower one. Jenkins's research laid the scientific groundwork for subsequent low-carbohydrate diets. In 1992, Atkins published an update from his 1972 book, Dr. Atkins' New Diet Revolution, and other doctors began to publish books based on the same principles. During the late 1990s and early 2000s, low-carbohydrate diets became some of the most popular diets in the US. By some accounts, up to 18% of the population was using one type of low-carbohydrate diet or another at the peak of their popularity. Food manufacturers and restaurant chains noted the trend, as it affected their businesses.

Sources: en.wikipedia.org

Supporting material

Xanthoria parietina serves as both a food source and shelter for certain gastropods. The snail Balea perversa uses the lichen for shelter and nourishment. Similarly, other gastropods, such as Helicigona lapicida, feed on Xanthoria parietina. This grazing may contribute to lichen dispersal: photobiont cells from X. parietina partially survive passage through the snail's digestive tract, retaining some photosynthetic activity even after digestion. Such survival raises the possibility that snail herbivory could facilitate lichen relichenization—either by recombining surviving symbionts from the same thallus or by mixing photobionts and mycobionts from different individuals in fecal deposits. However, digestion significantly reduces photobiont viability, with photobiont fluorescence (a measure of photosynthetic activity) declining by 41–44% after passage through the snail gut. While some cells remain intact, they often suffer morphological damage (including shrunken chloroplasts and enlarged cell wall-to-membrane distances), leaving it unclear whether surviving photobionts can effectively establish new lichens without viable fungal spores or hyphae.

===== ANTHEM-UC ===== The ANTHEM-UC study is a phase IIb trial evaluating icotrokinra in adults with moderately to severely active ulcerative colitis. The study met its primary endpoint of clinical response, with patients treated with the highest dose of icotrokinra achieving a response rate of 63.5% at week 12 versus 27% for placebo.

Miroslav Aleksić became mayor of Trstenik in 2012 as a member of the United Regions of Serbia (Ujedinjeni regioni Srbije, URS). The URS largely became dormant after the 2014 Serbian parliamentary election, and Aleksić left the party later in the year and became acting leader of a breakaway group initially called the People's Party of Serbia (Narodna stranka Srbije, NSS). The group was formally constituted as the People's Movement of Serbia in January 2015, and Aleksić was chosen as its leader in February. The party contested the 2016 parliamentary election as part of the Alliance for a Better Serbia list led by Boris Tadić, Čedomir Jovanović and Nenad Čanak. Aleksić received the eighth position on the electoral list and was elected when the alliance won thirteen mandates. The People's Movement of Serbia operated in a parliamentary alliance with Tadić's Social Democratic Party, which also contested the 2016 elections in the Alliance for a Better Serbia. Aleksić served as the parliamentary group's deputy leader. Both the alliance with the Social Democratic Party and Aleksić's deputy leadership of the parliamentary group continued after the party was restructured as the People's Party.

=== Dextran prodrug applications === These drug-polymer complexes have advantages such as longer drug half-life and improved targeted drug delivery. Dextran prodrugs have potential applications in the treatment of liver diseases, pulmonary diseases, colonic diseases, and cancer.

Sources: en.wikipedia.org

Frequently asked questions

What is semax derived from?

Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.

Is semax approved as a medicine?

It is registered for clinical use in Russia and a few other countries, typically as a nasal drop formulation. It does not hold approval from the United States Food and Drug Administration or the European Medicines Agency. Outside those markets it is generally handled as a research chemical.

Why is much of the research published in Russian?

The compound was developed in Moscow and the earliest studies were conducted there, so the primary literature is largely in Russian-language journals. Translation and indexing have been incomplete, which limits access for outside researchers. Independent groups have since published some work, but the total volume remains modest.

Why are single-use aliquots recommended?

Each freeze-thaw cycle can degrade a fraction of the peptide and promote aggregation. Dividing a stock solution into single-use volumes removes repeated cycling as a variable. It also limits the time a thawed solution spends at room temperature.

Network